CAV2-Cre (0.5 μl, 3 × 10
12 viral genomes per μl) was stereotaxically injected bilaterally into the dorsal striatum (0.5 mm anterior to Bregma, ± 1.75 mm lateral to midline, 3.0 mm ventral from the skull surface) using the Allen Mouse Brain Atlas as a guide.
41 (link) All animals used for behavioral experiments received striatal CAV2-Cre injection: CAV2-Cre injected
Slc17a6+/+ animals were used as controls (CAV2
Cre-
Slc17a6+/+ controls) and CAV2-Cre injected
Slc17a6lox/lox littermates were used to generate CAV2
Cre-
Slc17a6lox/lox mice.
For electrophysiological experiments, CAV2
Cre-
Slc17a6+/+ controls and CAV2
Cre-
Slc17a6lox/lox littermates also received stereotaxic injections of the opsin AAV2-EF1α-DIO-hChR2(H134R)-mCherry (0.5 μl AAV2-ChR2; 3 × 10
9 viral genomes per μl; UNC Vector Core) into the CL/CM/PF thalamic nuclei (−2.18 mm anterior to Bregma, ± 0.5 mm lateral to midline, 3.3 mm ventral from the skull surface).
During stereotaxic injections, animals were anesthetized with 1–2%
isoflurane (Kent Scientific, Torrington, CT) and with lidocaine/bupivacaine (1.0 mg/kg and 0.5 mg/kg s.c.). After surgeries, analgesia was supplied by ketoprofen (5.0 mg/kg, s.c.). All animals were allowed to recover from surgeries for 4 weeks before they were submitted to further experimental procedures.
Melief E.J., McKinley J.W., Lam J.Y., Whiteley N.M., Gibson A.W., Neumaier J.F., Henschen C.W., Palmiter R.D., Bamford N.S, & Darvas M. (2018). Loss of glutamate signaling from the thalamus to dorsal striatum impairs motor function and slows the execution of learned behaviors. NPJ Parkinson's Disease, 4, 23.